RecruitingNCT06887348

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

Sponsor

Replimune, Inc.

Enrollment

50 participants

Start Date

Dec 12, 2025

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma Melanoma Advanced Solid Tumor Metastatic Melanoma

Summary

This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term safety follow-up study for people who were previously treated with one of three experimental cancer therapies: RP1, RP2, or RP3 (oncolytic virus therapies — viruses engineered to attack cancer cells). Researchers want to track participants' health over many years after treatment ended. **You may be eligible if...** - You received at least one dose of RP1, RP2, or RP3 in a previous clinical trial - You have completed or officially withdrawn from that earlier study - You (or your legal guardian) are able to provide signed consent **You may NOT be eligible if...** - You did not participate in a prior RPx trial - You are unwilling or unable to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.